arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

BridgeBio Pharma, Inc.

BBIO Health Care Biotechnology: Pharmaceutical Preparations
$68.10
▲ +0.5% Today
as of Oct 23, 15:15 ET
Last 30 days -5.54% Sep 14 → Oct 23
$62.57 $65.21 $67.84 $70.47 $73.11 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$67.48
High
$69.32
Low
$67.07
Volume
$3M
Avg Vol
$3M
Mkt Cap
$13.0B
P/E (TTM)
—
Beta
—
52w High
$93.42
52w Low
$52.75
Div Yield
—
Shares Out
$195M

Recent Press Releases & News last 60 days · 25 items

Oct 22 · 11:30 PR GlobeNewswire
BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET
Oct 21 · 12:06 Zacks
The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics
Oct 20 · 15:12 Simply Wall St.
What BridgeBio Pharma Doubters Missed
▸ Show all 25 press releases & news Free account →

BBIO earnings at a glance

BridgeBio Pharma, Inc. (BBIO) is scheduled to report earnings on Wednesday, November 4, 2026 — in 12 days. Analysts expect earnings per share of -$0.67, compared with -$0.95 in the same quarter last year (+29%). The options market is pricing a move of about ±6.5% after the report, a range of roughly $63.68 to $72.52 from today's $68.10. Over its last 6 reports the stock rose the next day 1 time and fell 5, moving ±3.8% on average; after the most recent report on Aug 11, 2026 it moved -1.1%. That means options currently expect more movement than BBIO has typically delivered. BBIO beat the consensus EPS estimate in 1 of its last 6 reported quarters. Implied volatility is currently 55%. The share price of $68.10 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$53
$93
38% of range
Avg surprise (last 6)
-14.3%
Avg reaction (last 6)
-2.1%
17% positive
Latest IV / EM
55%
EM ±6.5% · $65 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.08$-0.56$-0.04$0.48$1.00 Actual $-0.92Actual $-0.98Actual $-1.08Actual $-0.20Actual $-0.39Actual $-0.86Actual $-0.88Est $1.00Actual $-0.95Est $-0.83Actual $-0.95Est $-0.88Actual $-1.00Est $-0.75Actual $-0.84Est $-0.70Actual $-0.78Est $-0.64 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-185M$-75M$35M$146M$256M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Aug 11, 2026Jun/2026 $-0.78 $-0.64 -21.9% +32.6% -1.1% earnings
Thu May 7, 2026Mar/2026 $-0.84 $-0.70 -20.0% +4.5% -0.1% earnings
Tue Feb 24, 20268K 2026-02-24 $-1.00 $-0.75 -33.3% — -2.6% earnings
Wed Oct 29, 2025Sep/2025 $-0.95 $-0.88 -8.0% — -4.9% earnings
Tue Aug 5, 2025Jun/2025 $-0.95 $-0.83 -14.5% — -8.9% earnings
Tue Apr 29, 2025Mar/2025 $-0.88 $1.00 +12.0% — +5.3% earnings
Mon Sep 30, 2024Sep 2024 $-0.86 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.39 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.20 — — — — financials
Sat Sep 30, 2023Sep 2023 $-1.08 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.98 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.92 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Wed Nov 4, 2026Sep/2026OTHER -$0.67-$0.95 +29.5%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$244M$195M—$121M$111M$117M—$3M
Cost of revenue$15M$10M—$7M$4M$3M—$598,000
Gross profit————————
Operating income$-107M$-106M—$-145M$-134M$-104M—$-192M
Net income$-156M$-167M—$-185M$-184M$-170M—$-164M
EPS (diluted)$-0.78$-0.84—$-0.95$-0.95$-0.88—$-0.86

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$678M$880M$570M$643M$749M$541M$681M$266M
Inventory$53M$33M$27M$25M$18M$4M$0—
Total current assets$1.09B$1.24B$798M$839M$912M$695M$721M$445M
Total assets$1.22B$1.37B$936M$998M$1.08B$882M$919M$665M
Long-term debt$2.65B$2.65B—$2.01B$0$0$437M$436M
Total liabilities$3.72B$3.64B$3.01B$2.92B$2.86B$2.52B$2.38B$1.88B
Total equity$-2.52B$-2.27B$-2.09B$-1.93B$-1.78B$-1.64B$-1.47B$-1.22B

Implied volatility — last 90 days

34%54%74%95%115% Jun 07 — IV 53% · EM ±7.3%Jun 08 — IV 51% · EM ±6.7%Jun 09 — IV 51% · EM ±6.4%Jun 10 — IV 48% · EM ±5.7%Jun 11 — IV 43% · EM ±4.7%Jun 12 — IV 40% · EM ±4.1%Jun 15 — IV 57% · EM ±4.1%Jun 16 — IV 64% · EM ±3.8%Jun 17 — IV 57% · EM ±2.4%Jun 19 — IV 44% · EM ±9.7%Jun 22 — IV 47% · EM ±9.7%Jun 23 — IV 46% · EM ±9.4%Jun 24 — IV 42% · EM ±8.4%Jun 25 — IV 42% · EM ±8.1%Jun 26 — IV 45% · EM ±8.6%Jun 29 — IV 46% · EM ±8.2%Jun 30 — IV 41% · EM ±7.0%Jul 01 — IV 43% · EM ±7.2%Jul 02 — IV 39% · EM ±6.3%Jul 03 — IV 40% · EM ±6.3%Jul 06 — IV 36% · EM ±5.0%Jul 07 — IV 44% · EM ±5.8%Jul 08 — IV 46% · EM ±5.7%Jul 09 — IV 51% · EM ±6.0%Jul 10 — IV 34% · EM ±3.8%Jul 13 — IV 56% · EM ±4.7%Jul 14 — IV 46% · EM ±3.3%Jul 15 — IV 86% · EM ±5.1%Jul 16 — IV 93% · EM ±3.9%Jul 20 — IV 52% · EM ±12.3%Jul 21 — IV 51% · EM ±11.8%Jul 22 — IV 49% · EM ±11.3%Jul 23 — IV 52% · EM ±11.7%Jul 24 — IV 50% · EM ±10.9%Jul 27 — IV 47% · EM ±9.9%Jul 28 — IV 51% · EM ±10.4%Jul 29 — IV 52% · EM ±10.4%Jul 30 — IV 57% · EM ±11.1%Jul 31 — IV 50% · EM ±9.6%Aug 03 — IV 67% · EM ±11.9%Aug 04 — IV 58% · EM ±10.0%Aug 05 — IV 57% · EM ±9.5%Aug 06 — IV 55% · EM ±8.8%Aug 07 — IV 49% · EM ±7.6%Aug 10 — IV 58% · EM ±8.1%Aug 11 — IV 48% · EM ±6.4%Aug 12 — IV 50% · EM ±6.3%Aug 13 — IV 42% · EM ±5.0%Aug 14 — IV 44% · EM ±4.9%Aug 17 — IV 45% · EM ±3.8%Aug 18 — IV 52% · EM ±3.8%Aug 19 — IV 64% · EM ±3.8%Aug 20 — IV 108% · EM ±4.5%Aug 24 — IV 47% · EM ±9.7%Aug 25 — IV 40% · EM ±8.1%Aug 26 — IV 48% · EM ±9.6%Aug 27 — IV 43% · EM ±8.5%Aug 28 — IV 43% · EM ±8.3%Aug 31 — IV 40% · EM ±7.1%Sep 01 — IV 43% · EM ±7.3%Sep 02 — IV 40% · EM ±6.7%Sep 03 — IV 40% · EM ±6.4%Sep 04 — IV 42% · EM ±6.5%Sep 07 — IV 47% · EM ±6.5%Sep 08 — IV 46% · EM ±6.0%Sep 09 — IV 48% · EM ±6.0%Sep 10 — IV 53% · EM ±6.2%Sep 11 — IV 59% · EM ±6.5%Sep 14 — IV 41% · EM ±3.5%Sep 15 — IV 81% · EM ±5.8%Sep 16 — IV 88% · EM ±5.2%Sep 17 — IV 116% · EM ±4.8%Sep 21 — IV 48% · EM ±10.1%Sep 22 — IV 39% · EM ±7.9%Sep 23 — IV 43% · EM ±8.6%Sep 24 — IV 45% · EM ±8.8%Sep 25 — IV 43% · EM ±8.3%Sep 28 — IV 43% · EM ±7.7%Sep 29 — IV 50% · EM ±8.6%Sep 30 — IV 50% · EM ±8.3%Oct 01 — IV 46% · EM ±7.4%Oct 02 — IV 57% · EM ±8.8%Oct 06 — IV 50% · EM ±6.6%Oct 07 — IV 54% · EM ±6.7%Oct 08 — IV 55% · EM ±6.5%

Sector peers

CORT
Corcept Therapeutics Incorporated
$12.9B $84.81-27.1%
SMMT
Summit Therapeutics Inc.
$14.4B $15.45-2.4%
ELAN
Elanco Animal Health Incorporated
$11.2B $22.75+0.9%
ASND
Ascendis Pharma A/S
$15.0B $242.81+1.6%
RDY
Dr. Reddy's Laboratories Ltd
$10.2B $13.21+0.2%
NUVL
Nuvalent, Inc.
$9.8B $123.96

BBIO earnings FAQ

When is BBIO's next earnings date?

BridgeBio Pharma, Inc. is expected to report on November 4, 2026.

What is BBIO's expected move for earnings?

Options currently price a move of about ±6.5%, or $4.42 per share either way from $68.10.

How does BBIO stock usually react to earnings?

Across the last 6 reports the average next-day move was ±3.8%, up 1 times and down 5 times.

What EPS are analysts expecting from BridgeBio Pharma, Inc.?

The consensus estimate is -$0.67 per share, versus -$0.95 a year ago.

What is BBIO's implied volatility?

BBIO's at-the-money implied volatility is about 55% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in